Company Articles and Overviews

Madrigal Pharmaceuticals Presents Buying Opportunity

Review on current status of Madrigal Pharmaceuticals and their recent drop in share price. I believe that this company has great potential to go back to its former glory of $300 as it currently sits under $200. NASH is a major market and MDGL is ahead of most competition, a market where there is currently no FDA approved drug.

Read More
Collin BeloinComment